In a groundbreaking advance poised to transform the landscape of radiopharmaceutical manufacturing, a collaborative team of scientists from the University of Missouri, Cancer Targeted Technology (CTT), and the Isotherapeutics Group (ITG) has devised an innovative, automated method to drastically accelerate the production of a novel prostate cancer therapeutic. This radiopharmaceutical, designated CTT1403, leverages the potent cancer-cell-killing properties of the radioactive isotope lutetium-177, paired with a highly specific targeting molecule that binds selectively to prostate cancer cells. This targeted approach minimizes collateral damage to healthy tissues, a hallmark challenge in conventional cancer therapies.
Central to this advancement is the reconsideration of the radiolabeling process, traditionally a painstaking and labor-intensive procedure that requires several hours of meticulous manual action to attach the radioactive lutetium-177 to a carrier molecule, known as a DOTA chelator, before combining it with the delicate targeting molecule. This conventional multi-step approach, involving elevated temperatures and cooling phases, often compromises the sensitive molecular architecture of the targeting agent due to its vulnerability to heat and acid conditions, presenting significant technical hurdles.
The research, spearheaded by Meltem Ocak and Carolyn Anderson at the University of Missouri’s Molecular Imaging and Theranostics Center, alongside CTT’s Bea Langton-Webster and ITG’s Jim Simón, introduces an ingenious single-step synthesis technique that simplifies and expedites this process. By chemically pre-linking the targeting molecule to the DOTA chelator, the team was able to radiolabel the compound by gently heating it to 60 degrees Celsius, an optimum temperature that preserves the structural integrity of the targeting moiety while allowing efficient chelation of lutetium-177.
This temperature-controlled reaction is seamlessly integrated into a commercially available automated synthesis unit housed at the University of Missouri Research Reactor (MURR), a facility renowned for its production of life-saving isotopes. The process thus reduces synthesis time from approximately six hours to a mere 38 minutes, dramatically enhancing production throughput and reproducibility. The automation not only curtails human exposure to radioactive materials, significantly improving operator safety, but also aligns with industry demands for scalable, standardized production methods requisite for extensive clinical trials.
Preclinical evaluations validated that this accelerated and automated radiolabeling method produces a radiopharmaceutical with efficacy comparable to that generated through traditional laborious techniques. This equivalency in therapeutic performance underscores the viability of the novel approach for ongoing and future clinical applications aimed at combatting advanced prostate cancer. The breakthrough presents a pivotal step toward realizing broader accessibility to targeted radiotherapies, which have been hitherto limited by complex manufacturing constraints.
Beyond the immediate application to CTT1403, this pioneering work sets a compelling precedent for the radiochemical synthesis of other targeted cancer therapeutics. The concept of developing pre-assembled chelator-targeting molecule conjugates amenable to lower-temperature and automated radiolabeling could be extrapolated to a spectrum of radiotherapeutics, expediting their bench-to-bedside translation.
Moreover, the portability of the synthesis apparatus heralds a vision where such systems could be deployed within clinical environments, such as hospitals and radiopharmacies, potentially enabling onsite production of personalized cancer treatments. This advancement promises to diminish logistical barriers and latency in drug delivery, ultimately enhancing patient access to innovative therapies in real time.
The University of Missouri’s confluence of expertise in isotopic production at MURR and radiopharmaceutical chemistry uniquely positions it as a fertile nexus for continued innovation in this domain. Carolyn Anderson, a distinguished professor and associate director at the Ellis Fischel Cancer Center, underscores the transformative impact of this work, highlighting the potential to replicate or adapt this radiolabeling protocol for diverse diagnostic and therapeutic agents using lutetium-177.
Recognition of this research includes accolades such as the Drs. Jane & Abass Alavi Mars Shot Research Award granted to Anderson, evidencing the scientific community’s appreciation for advancements in nuclear medicine and molecular imaging. The study appears in the prestigious journal Nuclear Medicine and Biology, providing a detailed blueprint of the automated one-step radiolabeling methodology, supported by funding from the National Cancer Institute.
As the oncology field increasingly gravitates toward precision medicine, methodologies that facilitate rapid, reliable, and safe synthesis of targeted radiotherapeutics will be indispensable. This research not only exemplifies such innovation but also accelerates the journey toward scalable clinical deployment of next-generation cancer treatments with enhanced efficacy and patient tolerability.
Subject of Research: People
Article Title: Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer
News Publication Date: 29-Jan-2026
Web References:
http://dx.doi.org/10.1016/j.nucmedbio.2026.109607
References:
National Cancer Institute (funder)
Image Credits:
University of Missouri
Keywords:
Biomedical engineering, Clinical medicine, Diseases and disorders, Health care, Human health, Medical specialties, Pharmaceuticals, Pharmacology, Health and medicine
Tags: accelerated cancer drug productionautomated lutetium-177 labeling methodautomated radiopharmaceutical manufacturingcancer-cell-specific targeting moleculesCTT1403 cancer drug candidateDOTA chelator radiolabelinglutetium-177 radiopharmaceuticalsminimizing healthy tissue damage cancer treatmentmolecular imaging and theranosticsprostate cancer radiotherapy advancementsprostate cancer targeted therapyradiolabeling process innovation
